<?xml version="1.0" encoding="UTF-8"?>
<soapenv:Envelope xmlns:soapenv="http://schemas.xmlsoap.org/soap/envelope/">
    <soapenv:Body>
        <stud:createStudy xmlns:stud="http://schema.integration.caaers.cabig.nci.nih.gov/study">
            <stud:studies>
                <stud:study>
                    <shortTitle>A Randomized Phase III Trial of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer</shortTitle>
                    <phaseCode>Phase III Trial</phaseCode>
                    <verbatimFirst>true</verbatimFirst>
                    <adeersReporting>true</adeersReporting>
                    <studyPurpose>Treatment</studyPurpose>
                    <aeTermUnique>true</aeTermUnique>
                    <stud:aeTerminology>
                        <stud:ctcVersion>
                            <name>4</name>
                        </stud:ctcVersion>
                    </stud:aeTerminology>
                    <stud:diseaseTerminology>
                        <diseaseCodeTerm>CTEP</diseaseCodeTerm>
                    </stud:diseaseTerminology>
                    <fundingSponsor>
                        <organizationAssignedIdentifier>
                            <value>E2100</value>
                        </organizationAssignedIdentifier>
                        <stud:studyFundingSponsor>
                            <stud:organization>
                                <name>Cancer Therapy Evaluation Program</name>
                                <nciInstituteCode>CTEP</nciInstituteCode>
                            </stud:organization>
                        </stud:studyFundingSponsor>
                    </fundingSponsor>
                    <coordinatingCenter>
                        <organizationAssignedIdentifier>
                            <value>E2100</value>
                        </organizationAssignedIdentifier>
                        <stud:studyCoordinatingCenter>
                            <stud:organization>
                                <name>Eastern Cooperative Oncology Group</name>
                                <nciInstituteCode>ECOG</nciInstituteCode>
                                <type>CGP</type>
                            </stud:organization>
                        </stud:studyCoordinatingCenter>
                    </coordinatingCenter>
                    <identifiers>
                        <stud:systemAssignedIdentifier>
                            <type>Other</type>
                            <value>E2100</value>
                            <primaryIndicator>false</primaryIndicator>
                            <systemName>CTEP-ESYS</systemName>
                        </stud:systemAssignedIdentifier>
                    </identifiers>
                    <treatmentAssignments>
                        <stud:treatmentAssignment>
                            <ctepDbIdentifier>11935</ctepDbIdentifier>
                            <code>ARMA1</code>
                            <description>ARM A (Cycle = 28 days): AD 6: patients enrolled after 1/12/04:

                                Paclitaxel 90 mg/m2 IV over 1hr on day 1qw x 3
                                Bevacizumab 10 mg/kg IV over 30-90 min on days 1&amp;15 q28d
                                NOTE: Pts who discontinue paclitaxel may continue bevacizumab.
                                Treatment may continue until disease progression or toxicity.</description>
                        </stud:treatmentAssignment>
                        <stud:treatmentAssignment>
                            <ctepDbIdentifier>11936</ctepDbIdentifier>
                            <code>ARMB1</code>
                            <description>ARM B (Cycle = 28 days): for pts enrolling after AD6, 1/12/04:

                                Paclitaxel 90 mg/m2 IV over 1hr on day 1qw x 3.
                                NOTE: Treatment may continue until disease progression or toxicity.</description>
                        </stud:treatmentAssignment>
                        <stud:treatmentAssignment>
                            <ctepDbIdentifier>8242</ctepDbIdentifier>
                            <code>ARM A</code>
                            <description>ARM A (Cycle = 28 days):
                                Paclitaxel 90 mg/m2 IV over 1hr on day 1qw x 3, for 18 cycles.
                                Bevacizumab 10 mg/kg IV over 30-90 min on days 1&amp;15 q28d, for 18 cycles.</description>
                        </stud:treatmentAssignment>
                        <stud:treatmentAssignment>
                            <ctepDbIdentifier>8243</ctepDbIdentifier>
                            <code>ARM B</code>
                            <description>ARM B (Cycle = 28 days):
                                Paclitaxel 90 mg/m2 IV over 1hr on day 1qw x 3, for 18 cycles.</description>
                        </stud:treatmentAssignment>
                    </treatmentAssignments>
                    <studyAgents>
                        <stud:studyAgent>
                            <stud:agent>
                                <nscNumber>673089</nscNumber>
                                <name>Paclitaxel (Taxol)</name>
                            </stud:agent>
                            <indType>NA_COMMERCIAL</indType>
                            <partOfLeadIND>
                                false
                            </partOfLeadIND>
                        </stud:studyAgent>
                        <stud:studyAgent>
                            <stud:agent>
                                <nscNumber>704865</nscNumber>
                                <name>Bevacizumab (rhuMAb VEGF)</name>
                            </stud:agent>
                            <indType>OTHER</indType>
                            <partOfLeadIND>
                                false
                            </partOfLeadIND>
                        </stud:studyAgent>
                    </studyAgents>
                    <studyDevices>
                        <stud:studyDevice>
                            <stud:device>
                                <commonName>Infusaport</commonName>
                                <brandName>Bardport</brandName>
                                <type/>
                                <ctepDbIdentifier>106</ctepDbIdentifier>
                                <status/>
                                <studyDeviceINDAssociations>
                                    <stud:studyDeviceINDAssociation>
                                        <stud:investigationalNewDrug>
                                            <indNumber/>
                                            <holderName>CTEP</holderName>
                                        </stud:investigationalNewDrug>
                                    </stud:studyDeviceINDAssociation>
                                </studyDeviceINDAssociations>
                            </stud:device>
                        </stud:studyDevice>
                    </studyDevices>
                    <otherInterventions/>
                    <ctepStudyDiseases>
                        <stud:ctepStudyDisease>
                            <stud:diseaseTerm>
                                <term>Invasive breast carcinoma</term>
                                <meddraCode>10006190</meddraCode>
                            </stud:diseaseTerm>
                            <leadDisease>true</leadDisease>
                        </stud:ctepStudyDisease>
                    </ctepStudyDiseases>
                </stud:study>
            </stud:studies>
        </stud:createStudy>
    </soapenv:Body>
</soapenv:Envelope>
